Clover Health Investments has become one of the more unusual setups in managed care: a 60% gain in a single month, shorts actively unwinding, and options traders turning the most cautious they have been in two years — all at the same time.
The price story is stark. CLOV closed at $3.50 on Tuesday, up 7% on the week and 60% higher than where it traded in early April. The move has come in bursts — a sharp rally off the $1.70 range in March, followed by a post-earnings gap on May 6 that lifted the stock around 8% in a day and 36% over five days. Close peers have largely gone the other way: AMN fell 8.7% on the week, UNH dropped 1.8%, and CVS gave back 1%. CLOV's outperformance versus the managed care group has been striking, and the divergence has widened further this week.
Shorts are backing away as the stock moves higher. SI as a percentage of free float has fallen from a peak near 9.6% in early April to 8.0% now — a steady, multi-week unwind rather than a single sharp squeeze. The 11% drop in short shares over the past week alone is meaningful. What keeps the lending market from looking dangerous is the borrow picture: cost to borrow is a negligible 0.42%, and availability has loosened sharply to 211% — more than twice the shares available than are currently borrowed. That compares with availability near 93% in early April, when the borrow was far tighter. The ORTEX short score has tracked the retreat in real time, sliding from 68 ten days ago to 60.7 now, though it remains elevated in absolute terms. Overall, positioning looks cautious but not crowded — shorts are retreating in an orderly fashion into the rally, not panicking.
The options market tells a more defensive story. The put/call ratio has climbed to 0.35, more than two standard deviations above its 20-day average of 0.28 — the most defensive reading on this metric in the trailing year, short of the 52-week high of 0.54. That is a notable shift from the call-heavy positioning that characterised April, and it suggests some market participants are hedging gains ahead of the June 10 earnings event rather than pressing further on the upside.
The Street is not exactly enthused. The mean price target of $3.15 now sits below the current price — analysts have consistently trimmed targets over the past year, with Canaccord Genuity cutting from $3.70 to $3.20 in March while holding its Buy rating, and Leerink Partners lowering to $2.50 at the same time. The stock has simply run past the consensus. The bull case centres on Clover Assist adoption: physicians using the AI-powered tool are recording an 8% medical cost ratio advantage over non-users, and 95%-plus member retention heading into 2026 underpins the profitability outlook for next year. Bears point to regulatory exposure in Medicare Advantage, execution risk on the CA rollout, and the company's history of dilutive equity issuance when cash gets tight. On valuation, the trailing P/E of 37x has expanded by roughly 10 turns over the past month — a direct function of the price move rather than an earnings upgrade cycle. EPS momentum scores are genuinely strong at the 91st–92nd percentile, but the quality pillar remains weak, with return on assets in negative territory.
Insider behaviour adds a wrinkle worth noting. The 90-day net insider position is technically positive — $2.4 million net bought — but the recent-trade log tells a different story. Every single transaction in the past five weeks has been a sale: the CEO, acting CFO, President, General Counsel, and an Independent Director have all been sellers into the rally, at prices ranging from $2.04 in April up to $3.52 this month. These appear to be smaller programmatic transactions rather than outright conviction sells, but the pattern is consistent and the direction is uniformly one way as the stock approaches levels not seen since mid-2024.
The next catalyst is the June 10 earnings call. The earnings history shows a clear pattern — the last print drove an 8% jump on the day and a 36% move over the following five days. With shorts still at 8% of float, borrow availability loosening, and options positioning edging more defensive, the setup heading into that date is the key thing to watch.
See the live data behind this article on ORTEX.
Open CLOV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
